Geneos Wealth Management’s Franklin Genomic Advancements ETF HELX Stock Holding History

Geneos Wealth Management’s Portfolio HELX Stock Details HELX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-85	Closed	-$2K	–	2265
2022 Q2	$2K	Hold	85	–	–	﹤0.01%	2391
2022 Q1	$3K	Hold	85	–	–	﹤0.01%	2461
2021 Q4	$4K	Hold	85	–	–	﹤0.01%	2458
2021 Q3	$4K	Buy	+85	New	+$4.6K	﹤0.01%	2504

Other funds holding HELX

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

BFEC

Benjamin F. Edwards & Company St. Louis, Missouri $5.69B AUM 15.37% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Geneos Wealth Management's HELX Position: Q3 2022 in Review

Geneos Wealth Management sold out of Franklin Genomic Advancements ETF (HELX) in Q3 2022, closing a stake of 85 shares — an estimated $2K sold.

Geneos Wealth Management first reported a position in HELX in Q3 2021 and held it in 4 quarters. The position peaked at $4K in Q4 2021. 9 funds tracked by Wall St. Rank hold HELX as of Q3 2022.

Geneos Wealth Management reported no remaining Franklin Genomic Advancements ETF position as of Q3 2022 after selling out during the quarter.
Geneos Wealth Management sold 85 Franklin Genomic Advancements ETF shares in Q3 2022, an estimated $2K.
Geneos Wealth Management first reported a position in Franklin Genomic Advancements ETF in Q3 2021 and held it in 4 quarters.
Geneos Wealth Management's Franklin Genomic Advancements ETF position peaked at $4K in Q4 2021.
9 funds tracked by Wall St. Rank held Franklin Genomic Advancements ETF as of Q3 2022.

Based on Geneos Wealth Management's 13F filing for Q3 2022, filed 14 Nov 2022.